



Epidemiology Data

May 2022

IMPORTANT NOTICE



For the purposes of this notice, “presentation” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“**Takeda**”) regarding this presentation. This presentation (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this presentation. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This presentation is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this presentation, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners.

This presentation contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

OVERVIEW OF EPIDEMIOLOGY DATA



ONCOLOGY

A red pill-shaped button with rounded ends. On the left, there is a white circle containing a red icon of a central node connected to five smaller nodes. To the right of the icon, the word "ONCOLOGY" is written in white, bold, uppercase letters.

GASTROENTEROLOGY (GI)






A white pill-shaped button with rounded ends and a thin grey border. On the left, there is a grey circle containing a red icon of a stylized human digestive tract. To the right of the icon, the text "GASTROENTEROLOGY (GI)" is written in black, bold, uppercase letters.

RARE GENETIC & HEMATOLOGY

A white pill-shaped button with rounded ends and a thin grey border. On the left, there is a grey circle containing a red icon of a DNA double helix. To the right of the icon, the text "RARE GENETIC & HEMATOLOGY" is written in black, bold, uppercase letters.

EPIDEMIOLOGY – NINLARO, ALUNBRIG, ADCETRIS & ICLUSIG



Product	Indication	Total Global Eligible Population (March 2022)	Geographies included
	R/R 2L+ Multiple Myeloma	~114,000 ¹	Japan, US, EU5, China
	ALK+ NSCLC	~36,000 ²	Japan, US, EU5, China
	HL – Front Line, ASCT Consolidation, 2L+; TCL - PTCL & R/R CTCL	~22,000 ³	Japan, EU5, China
	2L+ CML, ALL	~5,200 ⁴	US
	2L+ EGFR Exon20 Insertion+ NSCLC	~6,200 ⁵	Japan, US, EU5

3 | 1. R/R 2L+ MM label eligible patients; 2. ALK+ tested patients; 3. CD30+ label eligible patients - regulatory approval includes Stage IV/ITT Front Line Patients and High Risk HL consolidation patients; 4. 2L+ CP-CML, 3L+ AP/BP-CML, T315I+ CML, Ph+ ALL 5. EGFR Exon20 insertion+ mNSCLC patients whose disease has progressed on or after platinum-based chemotherapy.
Source: Takeda estimates. EU5 = France, Spain, Germany, Italy, UK

OVERVIEW OF EPIDEMIOLOGY DATA



ONCOLOGY




GASTROENTEROLOGY (GI)




RARE GENETIC & HEMATOLOGY


EPIDEMIOLOGY ULCERATIVE COLITIS (UC)



EPIDEMIOLOGY CROHN'S DISEASE (CD)



EPIDEMIOLOGY COMPLEX CROHN'S PERIANAL FISTULA (CPF)



OVERVIEW OF EPIDEMIOLOGY DATA



ONCOLOGY




GASTROENTEROLOGY (GI)



RARE GENETIC & HEMATOLOGY


EPIDEMIOLOGY HEREDITARY ANGIOEDEMA

TAKHZYRO[®]
(lanadelumab-flyo) injection




EPIDEMIOLOGY GAUCHER'S DISEASE: GLOBAL, CHINA/INDIA NOT INCLUDED

VPRIV[®]
velagluconase alfa
for injection



EPIDEMIOLOGY FABRY'S DISEASE: EX-US REGION, CHINA/INDIA NOT INCLUDED

REPLAGAL[®]
agalsidase alfa




EPIDEMIOLOGY HUNTER'S DISEASE: GLOBAL, INDIA/CHINA NOT INCLUDED

elaprase[®]
(idursulfase)




MPS II Patients




EPIDEMIOLOGY HEMOPHILIA A



Hemophilia A without inhibitors



EPIDEMIOLOGY CYTOMEGALOVIRUS (CMV) INFECTION IN POST-TRASPLANT





Better Health, Brighter Future